85977-49-7
Chemical Structure
Tauromustine
- CAS No.: 85977-49-7
- Formula:C7H15ClN4O4S
- Molecular Weight:286.74
IUPAC Name: 2-(3-(2-chloroethyl)-3-nitrosoureido)-N,N-dimethylethane-1-sulfonamide
InChIKey: RCLLNBVPCJDIPX-UHFFFAOYSA-N
SMILES: O=NN(CCCl)C(NCCS(=O)(N(C)C)=O)=O
Biological Activity: Tauromustine is an orally active nitrosourea anticancer agent. Tauromustine has an alkylation effect and can damage the DNA function. Tauromustine has a high therapeutic index, especially in the study of Walker 256 rat sarcoma. It is also active against melanoma, breast cancer, pleural mesothelioma and ovarian cancer. Tauromustine is mainly metabolized in the liver, but some of its metabolites also have cytotoxicity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tauromustine | Tauromustine is an orally active nitrosourea anticancer agent. Tauromustine has an alkylation effect and can damage the DNA function. Tauromustine has a high therapeutic index, especially in the study of Walker 256 rat sarcoma. It is also active against melanoma, breast cancer, pleural mesothelioma and ovarian cancer. Tauromustine is mainly metabolized in the liver, but some of its metabolites also have cytotoxicity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Gregor A, et al. Phase II study of tauromustine in malignant glioma. Eur J Cancer. 1992;28A(12):1959-62. [Content Brief]
- [2]. Smyth JF, et al. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol. 1995 Nov;6(9):948-9. [Content Brief]
- [3]. Bibby MC, et al. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice. Br J Cancer. 1992 Mar;65(3):347-50. [Content Brief]
Keywords
